Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
96 hedge funds and large institutions have $168M invested in Surface Oncology, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 29 increasing their positions, 16 reducing their positions, and 26 closing their positions.
81% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 16
27% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 26
19% more call options, than puts
Call options by funds: $3.45M | Put options by funds: $2.9M
14% more capital invested
Capital invested by funds: $147M → $168M (+$20.2M)
7% more funds holding
Funds holding: 90 → 96 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$12.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.59M |
| 3 |
Morgan Stanley
New York
|
+$4.05M |
| 4 |
State Street
Boston,
Massachusetts
|
+$3.22M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$4.52M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.85M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.31M |
| 4 |
DLPIC
Davide Leone & Partners Investment Company
London,
United Kingdom
|
-$2.1M |
| 5 |
HF
HRT Financial
New York
|
-$1.28M |
SURF Hedge Fund Activity: Q2 2021 in Review
96 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q2 2021, worth a combined $168M — up 14% from $147M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new SURF positions and 26 closed out — a net gain of 7 holders — while 29 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $12.2M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $4.52M sold.
- 96 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q2 2021, up from 90 in Q1 2021.
- Funds reported $168M of Surface Oncology, Inc. Common Stock stock for Q2 2021, up 14% quarter-over-quarter.
- 33 funds opened new Surface Oncology, Inc. Common Stock positions in Q2 2021 and 26 closed out, a net change of +7 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q2 2021 was BlackRock, an estimated $12.2M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q2 2021 was Acadian Asset Management, an estimated $4.52M sold.
Based on aggregated 13F filings for Q2 2021.